Clinical Trials

Papers
(The H4-Index of Clinical Trials is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Industry payments and brand-name tyrosine kinase inhibitor use amid generic entry65
Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial54
A critique on “A randomized evaluation of on-site monitoring nested in a multinational randomized trial”50
Stakeholder views about the responsibilities of principal investigators in multicenter randomized controlled trials48
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials28
A review of current practice in the design and analysis of extremely small stepped-wedge cluster randomized trials26
Dose finding in early-phase human immunodeficiency virus type 1 prevention monoclonal antibody clinical trials26
Topic-specific living databases of clinical trials: A scoping review of public databases24
Characterization of studies considered and required under Medicare’s coverage with evidence development program22
A Bayesian adaptive design approach for stepped-wedge cluster randomized trials22
Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials22
Importance of patient engagement in the conduct of pragmatic multicenter randomized controlled trials: The ADAPTABLE experience21
How is missing data handled in cluster randomized controlled trials? A review of trials published in the NIHR Journals Library 1997–202420
Training the next generation of clinical trial biostatisticians20
Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies19
Partner engagement for planning and development of non-pharmacological care pathways in the AIM-Back trial18
Unresolved issues with noninferiority pragmatic trials: Results of a literature survey16
0.55581593513489